Akers stock: buy or sell?

AKER stock price: $3.03 4.48% At close on February 26th, 2020

Updated on:
February 26th, 2020


After sliding a chilling -8.97% yesterday, Akers closed today at $3.03 and rocketed an outstanding 4.48%.

Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States and internationally.

Should I buy Akers stock?

You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. That's why is so important to define your own trading strategy that fits your character as inversor. At Stocks2.com, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.

Currently, Akers stock doesn't match any of these trading strategies, so our recommendation is not to buy.

Buy setupElegible
New all-time highNo
New 52 week highNo
Price crossing up 200d MANo
100d MA crossing up 200d MANo
This doesn't mean AKER will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems.

Is Akers stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. Unfortunately, we couldn't detect any rating for AKER stock for the last 30 days.

Akers stock analysis

Daily outlook

After sliding a chilling -8.97% yesterday, Akers closed today at $3.03 and rocketed an outstanding 4.48%.

After sliding a chilling -8.97% yesterday, Akers closed today at $3.03 and rocketed an outstanding 4.48%.

AKER stock chart (daily)

Weekly outlook

After boosting an exceptional 9.33% in a week last week, Akers Biosciences closed this week at $3.03 and plunged a dreadful -11.66%.

Akers Biosciences stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies. Since price and 20-weeks moving average lines crossed down late September 2019, AKER fell $-8.90 per share (-74.60%).

AKER stock chart (weekly)

Akers stock price history

Akers IPO was on January 23rd, 2014 at $1,086.72 per share1. Since then, AKER stock declined a -99.70%, with a yearly average of -16.60%.

1: Adjusted price after possible price splits or reverse-splits.

Akers stock historical price chart

AKER stock reached 52-week highs on March at $30.24, and all-time highs 2014-01-23 with a price of 1094.4.

Akers stock price target

How much a stock will be priced tomorrow or next week is quite unpredictable However, banks and other financial institutions analysts, with the help of lots of data and algorithms do their best to predict the stock prices movement. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. For the last 30 days we have not found any price target for Akers stock by any trusted analyst.

Financials and fundamental analysis

Earnings date and Earnings per Share

After presenting its last earnings report on April, Akers Biosciences . Unfortunately, reported EPS is not yet available in our database.
AKER earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

Compared to 2017, last anual revenues report draw a dreadful decrease of -50.35% to $1.67 million dollars. When comparing 2018 vs 2017, in line, profit margin (that is, the net income divided by revenues) plummed a -431.79% to -651.37%.

AKER annual Sales and Income evolution
2012$1.52 M-$-2.45 M-161.2%-
2013$3.58 M135.53%$-1.53 M-42.7%-37.55%
2014$4.43 M23.66%$-3.13 M-70.6%104.39%
2015$2.12 M-52.23%$-9.31 M-440.3%197.77%
2016$2.96 M39.99%$-3.30 M-111.6%-64.52%
2017$3.35 M13.30%$-7.37 M-219.6%122.98%
2018$1.67 M-50.35%$-10.85 M-651.4%47.28%

Quarterly financial results

Akers posted $0.28 M in revenues for 2018-Q4, a -49.85% decline compared to previous quarter. Reported quarter income marked $-3.84 million with a profit margin of -1,373.50%. Profit margin plunged a -819.92% compared to previous quarter when profit margin was -553.58%. When comparing sales to same quarter last year, Akers Biosciences sales marked a hair-raising correction and collapsed a -70.24%.
AKER quarterly Sales and Income evolution
2017-Q1$0.67 M-$-1.35 M-202.3%-
2017-Q2$1.07 M60.36%$-0.82 M-76.4%-39.41%
2017-Q3$0.68 M-36.84%$-1.18 M-174.3%43.96%
2017-Q4$0.94 M38.91%$-4.02 M-428.4%241.48%
2018-Q1$0.30 M-67.78%$-1.86 M-614.9%-53.75%
2018-Q2$0.53 M74.10%$-2.07 M-392.6%11.15%
2018-Q3$0.56 M5.79%$-3.08 M-553.6%49.17%
2018-Q4$0.28 M-49.85%$-3.84 M-1373.5%24.44%

Akers ownership

When you are planning to invest in a stock, it's always worth to have a look its ownership structure.

Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Akers, 6.72% of all outstanding shares are owned by its staff.

In case of Akers Biosciences stock, 28.26% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for AKER stock account 0.00%, no big difference from last month.

For a better understanding, the next table shows ownership data compared to other related companies:

Market cap$5.3 M
Total shares1.7 M
Float shares0.2 M
  - Institutional holdings (%)28.3%
  - Insider holdings (%)6.7%
Shares in short selling0.0%

Akers summary

Wednesday, February 26th, 2020
Day range$2.90 - $3.13
Previous close$2.90
Session gain4.48%
Average true range$0.29
50d mov avg$3.24
100d mov avg$5.56
200d mov avg$8.74
Daily pattern
Weekly pattern lt06a

Akers performance

To measure stock performance is always good to benchmark with competitors or related stocks. In the following table, we compare Akers Biosciences to :
AKERAkers Biosciences-60.65%-70.64%-86.19%

Akers competitors

Unfortunately, we could not find any public company that could be defined as Akers competitor. This doesn't mean Akers does not have any competitor in the market, it's just we could not detected it.